Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Authors

• Ashenafi Bulle, Washington University School of Medicine in St. Louis
• Peng Liu, Washington University School of Medicine in St. Louis
• Kuljeet Seehra, Washington University School of Medicine in St. Louis
• Sapana Bansod, Washington University School of Medicine in St. Louis
• Yali Chen, Washington University School of Medicine in St. Louis
• Kiran Zahra, Washington University School of Medicine in St. Louis
• Vikas Somani, Washington University School of Medicine in St. Louis
• Iftikhar Ali Khawar, Washington University School of Medicine in St. Louis
• Hung-Po Chen, Washington University School of Medicine in St. Louis
• Paarth B Dodhiawala, Washington University School of Medicine in St. Louis
• Lin Li, Washington University School of Medicine in St. Louis
• Yutong Geng, Washington University School of Medicine in St. Louis
• Chia-Kuei Mo, Washington University School of Medicine in St. Louis
• Jay Mahsl, Washington University School of Medicine in St. Louis
• Li Ding, Washington University School of Medicine in St. Louis
• Ramaswamy Govindan, Washington University School of Medicine in St. Louis
• Sherri Davies, Washington University School of Medicine in St. Louis
• Jacqueline Mudd, Washington University School of Medicine in St. Louis
• William G Hawkins, Washington University School of Medicine in St. Louis
• Ryan C Fields, Washington University School of Medicine in St. Louis
• David G DeNardo, Washington University School of Medicine in St. Louis
• Jason M Held, Washington University School of Medicine in St. Louis
• Patrick M Grierson, Washington University School of Medicine in St. Louis
• Andrea Wang-Gillam, Washington University School of Medicine in St. Louis
• Marianna B Ruzinova, Washington University School of Medicine in St. Louis
• Kian-Huat Lim, Washington University School of Medicine in St. Louis
• et al.

Journal

Nature Communications

Publication Date

3-20-2024

Volume

15

Issue

1

First Page

2503

Document Type

Open Access Publication

DOI

10.1038/s41467-024-46811-w

Rights and Permissions

Bulle, A., Liu, P., Seehra, K. et al. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Nat Commun 15, 2503 (2024). https://doi.org/10.1038/s41467-024-46811-w This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Bulle, Ashenafi; Liu, Peng; Seehra, Kuljeet; Bansod, Sapana; Chen, Yali; Zahra, Kiran; Somani, Vikas; Khawar, Iftikhar Ali; Chen, Hung-Po; Dodhiawala, Paarth B; Li, Lin; Geng, Yutong; Mo, Chia-Kuei; Mahsl, Jay; Ding, Li; Govindan, Ramaswamy; Davies, Sherri; Mudd, Jacqueline; Hawkins, William G; Fields, Ryan C; DeNardo, David G; Held, Jason M; Grierson, Patrick M; Wang-Gillam, Andrea; Ruzinova, Marianna B; Lim, Kian-Huat; and et al., "Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer." Nature Communications. 15, 1. 2503 (2024).
https://digitalcommons.wustl.edu/oa_4/3577

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.